Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.
暂无分享，去创建一个
B. Cheson | M. Maris | A. Lesokhin | J. Zonder | R. Ramchandren | S. Iyer | G. Lin | Erlene K Seymour | Y. Shou | K. Patel | Tina Catalano | G. Keudell